UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
|Videos|September 15, 2020
Investigational Treatment Shows Potential to Supress Memory Loss
Author(s)Aaron H. Burstein, PharmD
Aaron Burstein, PharmD, shares details from a scientific presentation at the Alzheimer's Association International Conference.
Advertisement
MENTAL HEALTH MINUTE
Aaron Burstein, PharmD, senior vice president of
Advertisement
Related to this article
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5